RxDoctor Payments Data

William Thompson, MD

Sleep Medicine · Meridian, IDNPI 1770594186

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $208 of the $249 with a category attached, or 83.6%. It is spread thinly across 12 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $194 and has fallen 85.5% since, to $28 in 2022.

$249in general payments, 2019–2025

Across 15 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$38
  • Grifols USA, LLC$30
  • United Therapeutics Corporation$30
  • Resmed Corp$28
  • GSK$23
  • Boehringer Ingelheim$19
  • plus $80 from 6 others

What the payments were for

  • Food & beverage$20884%
  • Education$4116%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few sleep medicine providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$36,015
Medicare patients
296
Services billed
398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat12$165,550
Arnuity ElliptaFluticasone Furoate16$3,710
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$2,931
Dextroamphetamine Sulfate12$2,732
Albuterol Sulfate HfaAlbuterol Sulfate29$896
Modafinil18$648
Gabapentin25$471
Ropinirole Hcl14$420
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine13$387
Clonazepam46$285
Zolpidem Tartrate23$178
Famotidine11$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArnuity Ellipta$23$3,71016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few sleep medicine providers in Idahoon file to place this against a meaningful peer group, so we don't.

Other sleep medicine in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →